Detail of the clinical trial

Title of the trial A Phase III Randomized, Open Label, Multi-center Study of the Safety and Efficacy of Apixaban for Thromboembolism Prevention versus No Systemic Anticoagulant Prophylaxis during Induction Chemotherapy in Children with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) or Lymphoma (T or B cell) Treated with Asparaginase
EudraCT number 2014-000328-47
Protocol number CV185-155
Sponsor Bristol-Myers Squibb International Corporation, Chaussée de La Hulpe 185, 1170 Brussels, Belgium
Indications Oncology
Diagnosis Acute Lymphoblastic Leukemia, Lymphoma
Population in clinical trial Infants and Toddlers (28 days - 23 months)
Children (2-11 years)
Adolescents (12-17 years)
Year of receiving the request to Institute (SÚKL) 2019
Date of approval by Institute (SÚKL) 10.9.2019
Date of approval by EC 17.4.2019
Date of initiation CT in ČR
Date of ending CT in ČR
Sites Fakultní nemocnice Brno,Klinika dětské onkologie,Černopolní 9,Brno,613 00

‹‹ Back to list